
Entrada Therapeutics, Inc. (TRDA) Market Cap
Entrada Therapeutics, Inc. has a market capitalization of $490.4M.
Financials based on reported quarter end 2025-12-31
Price: $12.81
βΌ -0.24 (-1.84%)
Market Cap: 490.42M
NASDAQ Β· time unavailable
CEO: Dipal Doshi
Sector: Healthcare
Industry: Biotechnology
IPO Date: 2021-10-29
Website: https://www.entradatx.com
Entrada Therapeutics, Inc. (TRDA) - Company Information
Market Cap: 490.42M Β· Sector: Healthcare
Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead product candidate is ENTR-601-44, which is in preclinical trail for the treatment of Duchenne muscular dystrophy and myotonic dystrophy type 1. It also engages in the development of EEV-PMO-CAG for the treatment of myotonic dystrophy type 1. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.
Analyst Sentiment
Based on 5 ratings
Analyst 1Y Forecast: $18.00
Average target (based on 2 sources)
Consensus Price Target
Low
$13
Median
$20
High
$21
Average
$18
Potential Upside: 40.5%
Price & Moving Averages
Related Companies in Healthcare
Fundamentals Overview
π AI Financial Analysis
Powered by StockMarketInfo"TRDAβs latest quarter (2025-12-31) reported Revenue of ~$1.30M and Net Income of -$39.2M (EPS: -0.95). On a QoQ basis, revenue declined from ~$1.61M (2025-09-30) to ~$1.30M (2025-12-31), a -19.6% change, while losses narrowed from -$44.1M to -$39.2M (Net income improvement of ~+11.3% QoQ; i.e., less negative). Across the full 4-quarter period, revenue trended down sharply from ~$20.6M (2025-03-31) to ~$1.30M (2025-12-31), while EPS losses fluctuated but remained material. Profitability remains weak: net margins are deeply negative, with EPS staying negative throughout. Cash flow quality is also challengingβFCF stayed consistently negative (about -$40.0M to -$28.1M during the period, ending at -$32.0M). There were no dividends paid. Balance-sheet resilience appears mixed: total assets fell from ~$486.5M to ~$377.4M over the period, and equity declined from ~$417.3M to ~$306.1M. However, net debt remains negative throughout (net cash position), which helps liquidity. Shareholder returns are the standout: the stockβs 1Y performance is +76.6% (strong momentum), supporting a better total-return score despite ongoing operating losses. Revenue and earnings-based metrics were not applicable for this analysis due to the company's pre-revenue status. The evaluation focused on cash runway, burn rate, and market sentiment instead."
Revenue Growth
Revenue fell materially over the 4-quarter span (~$20.6M to ~$1.30M; -93.7%). QoQ for latest quarter: -19.6% vs prior quarter. YoY growth not computable from the provided data (no prior-year quarter provided).
Profitability
Net income remains negative every quarter (latest: -$39.2M; EPS -0.95). Latest QoQ loss narrowed (~+11.3% improvement), but overall margins are deeply negative across the period.
Cash Flow Quality
FCF is consistently negative, indicating ongoing cash burn (latest FCF ~-$32.0M). No dividends and no buyback data provided; cash burn remains a key risk.
Leverage & Balance Sheet
Total assets and equity declined over the period, but net debt stayed negative throughout (net cash position). This supports resilience, though balance-sheet contraction is a watch item.
Shareholder Returns
Strong total-return momentum: 1Y price change of +76.6% (well above +20% threshold). No dividend yield provided; buybacks not disclosed.
Analyst Sentiment & Valuation
Consensus price target ~$18 vs current ~$13.99 implies upside of ~28.6%. Valuation support is constructive, though earnings power is not evident given persistent losses.
Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.





